We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
Read MoreHide Full Article
Key Takeaways
REGN's melanoma combo study missed the primary goal of significantly improving PFS.
High-dose fianlimab combo showed 11.5-month median PFS versus 6.4 months for Keytruda.
Regeneron continues a phase III trial comparing the combo directly against Opdualag.
Regeneron Pharmaceuticals (REGN - Free Report) announced that the late-stage study evaluating the combination of fianlimab and cemiplimab in first-line unresectable locally advanced or metastatic melanoma failed to meet the primary endpoint of statistically significant improvement in progression-free survival (PFS) versus Merck’s (MRK - Free Report) Keytruda (pembrolizumab) monotherapy.
Fianlimab is a LAG-3 inhibitor while cemiplimab is a PD-1 inhibitor.
The detailed results from the study will be presented at an upcoming medical meeting.
More on REGN’s Phase III Melanoma Study
The randomized, double-blind phase III study is evaluating fianlimab in combination with cemiplimab against pembrolizumab in treatment-naïve patients aged 12 years and older with unresectable locally advanced or metastatic melanoma.
A total of 1,546 patients were enrolled and randomized to receive either high-dose fianlimab (1,600 mg) plus cemiplimab (350 mg) every three weeks, low-dose fianlimab (400 mg) plus cemiplimab (350 mg) every three weeks, pembrolizumab monotherapy (200 mg every three weeks) with placebo, or cemiplimab monotherapy (350 mg every three weeks) with placebo.
Despite missing statistical significance, the high-dose fianlimab combination demonstrated a numerical improvement in median PFS of 11.5 months compared with 6.4 months for pembrolizumab alone, translating to a 5.1-month. No new safety concerns were identified for the combination therapy.
The results represent a setback for Regeneron’s efforts to strengthen its position in the competitive melanoma immunotherapy market, where established PD-1/LAG-3 combinations such as Bristol Myers Squibb (BMY - Free Report) Opdualag have already gained traction.
Regeneron continues to advance the program through an ongoing phase III head-to-head trial comparing the high-dose fianlimab and cemiplimab combination directly against Opdualag in first-line advanced melanoma. Positive outcomes from that study could still support the long-term commercial opportunity for the regimen despite the current trial miss.
Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive the long-term growth of Keytruda.
BMY’s Opdualag is a combination of nivolumab and relatlimab. The drug is indicated for treating adults who have a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma) and children who are 12 years of age and older, who have melanoma that has spread or cannot be removed by surgery (advanced melanoma).
Sales of Opdualag have been robust as the drug continues to serve as a standard of care in first-line melanoma.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron is also actively strengthening its oncology portfolio to further diversify its revenue base. The company’s oncology franchise recently gained momentum following the label expansion of Libtayo, helping offset headwinds in the ophthalmology segment.
Regeneron’s first-quarter performance was encouraging, with overall revenues rising despite continued decline in sales of its flagship product, Eylea. This performance underscores the resilience and breadth of the company’s diversified portfolio.
Regeneron’s shares have lost 9.6% so far this year compared with the industry’s decline of 1.6%.
Image Source: Zacks Investment Research
However, Eylea sales remain under pressure amid intensifying competition from Roche’s Vabysmo, which has seen strong and rapid uptake. Vabysmo was designed to inhibit both Ang-2 and VEGF-A pathways, offering a differentiated mechanism that has resonated with physicians.
View the Zacks #1 Rank List
Image: Bigstock
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
Key Takeaways
Regeneron Pharmaceuticals (REGN - Free Report) announced that the late-stage study evaluating the combination of fianlimab and cemiplimab in first-line unresectable locally advanced or metastatic melanoma failed to meet the primary endpoint of statistically significant improvement in progression-free survival (PFS) versus Merck’s (MRK - Free Report) Keytruda (pembrolizumab) monotherapy.
Fianlimab is a LAG-3 inhibitor while cemiplimab is a PD-1 inhibitor.
The detailed results from the study will be presented at an upcoming medical meeting.
More on REGN’s Phase III Melanoma Study
The randomized, double-blind phase III study is evaluating fianlimab in combination with cemiplimab against pembrolizumab in treatment-naïve patients aged 12 years and older with unresectable locally advanced or metastatic melanoma.
A total of 1,546 patients were enrolled and randomized to receive either high-dose fianlimab (1,600 mg) plus cemiplimab (350 mg) every three weeks, low-dose fianlimab (400 mg) plus cemiplimab (350 mg) every three weeks, pembrolizumab monotherapy (200 mg every three weeks) with placebo, or cemiplimab monotherapy (350 mg every three weeks) with placebo.
Despite missing statistical significance, the high-dose fianlimab combination demonstrated a numerical improvement in median PFS of 11.5 months compared with 6.4 months for pembrolizumab alone, translating to a 5.1-month. No new safety concerns were identified for the combination therapy.
The results represent a setback for Regeneron’s efforts to strengthen its position in the competitive melanoma immunotherapy market, where established PD-1/LAG-3 combinations such as Bristol Myers Squibb (BMY - Free Report) Opdualag have already gained traction.
Regeneron continues to advance the program through an ongoing phase III head-to-head trial comparing the high-dose fianlimab and cemiplimab combination directly against Opdualag in first-line advanced melanoma. Positive outcomes from that study could still support the long-term commercial opportunity for the regimen despite the current trial miss.
Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive the long-term growth of Keytruda.
BMY’s Opdualag is a combination of nivolumab and relatlimab. The drug is indicated for treating adults who have a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma) and children who are 12 years of age and older, who have melanoma that has spread or cannot be removed by surgery (advanced melanoma).
Sales of Opdualag have been robust as the drug continues to serve as a standard of care in first-line melanoma.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote
REGN’s Efforts to Diversify Portfolio
Regeneron is also actively strengthening its oncology portfolio to further diversify its revenue base. The company’s oncology franchise recently gained momentum following the label expansion of Libtayo, helping offset headwinds in the ophthalmology segment.
Regeneron’s first-quarter performance was encouraging, with overall revenues rising despite continued decline in sales of its flagship product, Eylea. This performance underscores the resilience and breadth of the company’s diversified portfolio.
Regeneron’s shares have lost 9.6% so far this year compared with the industry’s decline of 1.6%.
Image Source: Zacks Investment Research
However, Eylea sales remain under pressure amid intensifying competition from Roche’s Vabysmo, which has seen strong and rapid uptake. Vabysmo was designed to inhibit both Ang-2 and VEGF-A pathways, offering a differentiated mechanism that has resonated with physicians.
REGN’s Zacks Rank
Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.